Pheast Therapeutics

Executive Summary

Pheast Therapeutics is a preclinical-stage biotechnology company pioneering innate immune checkpoint inhibitors that activate macrophages to combat cancer. Leveraging the discovery of CD24 as a “don’t eat me” signal by its Stanford founders, the company is developing first-in-class antibodies that block CD24 to enhance macrophage-mediated phagocytosis of tumor cells. This approach targets a novel innate immune checkpoint distinct from the CD47-SIRPα axis, potentially offering improved efficacy and safety in aggressive cancers that evade conventional immunotherapies. The lead anti-CD24 program is advancing toward phase 1 clinical trials, with IND-enabling studies underway. Pheast’s platform also includes earlier-stage macrophage-targeted candidates for additional indications. If successful, CD24 blockade could become a backbone of innate immune checkpoint therapy, particularly in cancers where CD24 is highly expressed. The company is well-positioned to address significant unmet need and has attracted top-tier investors. Near-term value drivers include initial phase 1 data and potential partnership or financing events.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead anti-CD24 antibody50% success
• Q4 2026Series B financing round70% success